Encochleated amikacin - Matinas BioPharma

Drug Profile

Encochleated amikacin - Matinas BioPharma

Alternative Names: C-Amikacin; MAT 2501

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Mycobacterial infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 15 Nov 2017 Matinas BioPharma plans a phase I multiple-ascending dose, pharmacokinetics, tolerability trial in healthy volunteers in the second quarter of 2018
  • 08 Aug 2017 Matinas BioPharma plans a phase II trial for Mycobacterial infections (Non-tuberculous) in the fourth quarter of 2018
  • 05 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top